Navigation Links
aTyr Pharma to Present at BioPharm America 2009
Date:9/14/2009

SAN DIEGO, Sept. 14 /PRNewswire/ -- aTyr Pharma, Inc., a biopharmaceutical company discovering and developing a new class of naturally occurring proteins as biotherapeutics, will present at the BioPharm America 2009 conference in San Francisco, CA on Friday, September 18th. Jeff Watkins, CEO of aTyr Pharma, will present an overview of aTyr Pharma's technology, product engine, and lead program based on naturally occurring resected proteins of the tRNA synthetases. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.

According to Cheryl Quinn, Director of Business Development at aTyr Pharma, "Because our product engine is based on the emerging new science of resectin proteins, we look forward to introducing aTyr Pharma's exciting new science and portfolio to the attendees of BioPharma America."

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV
2. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
3. Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
4. NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009
5. ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
6. StoredIQ Shares Expertise at IQPCs eDiscovery Pharma, Biotech and Medical Device Conference
7. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
8. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
9. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
10. Rib-X Pharmaceuticals to Present at the 49th ICAAC
11. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Vilnius, Lithuania, announced today that they have entered into a multiyear collaboration to ... provide CRISPR researchers with additional tools for gene editing across all applications. , ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
Breaking Biology Technology:
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):